This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners & Losers: ImClone

In previous studies, Provenge has been shown to have a delayed positive impact on survival. Based on this, CEO Mitch Gold said the interim results are promising.

Next, Genentech (DNA) and OSI Pharmaceuticals (OSIP) said that a late-stage study found that a combination of cancer drugs Avastin and Tarceva as a second-line treatment in patients with advanced lung cancer failed to increase the overall survival rate.

The "BeTa Lung" study looked at Avastin in combination with Tarceva in comparison to Tarceva alone in patients for whom chemotherapy had not stopped cancer progression. Median survival in the Tarceva and placebo group was 9.2 months. The companies said the median survival in the combination arm was similar but did not give specific data. The full data will be presented at a U.S. conference in November.

Wall Street analysts said that the trial's potential success wasn't factored into any Genentech revenue estimates, giving Monday's outcome little impact. Genentech shares were down $4.40, or 5%, at $83.13. OSI shares lost value on the study data, shedding $7.90, or 17%, at $37.94.

Also Monday, Salix Pharmaceuticals Ltd. (SLXP) said at the American College of Gastroenterology that its rifaximin met its goals improving quality of life for patients with irritable bowel syndrome in a midstage clinical trial. Its shares were up $1.09, or 19.2%, at $6.77.

And CombinatoRx Inc (CRXX) shares plunged $2.22, or 74%, to 78 cents, after osteoarthritis drug Synavive missed its main goal in a midstage trial, as it didn't significantly improve knee symptoms vs. placebo.

2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs